Randomized Phase IIA Trial of Gemcitabine Compared With Bleomycin Plus Vincristine for Treatment of Kaposi’s Sarcoma in Patients on Combination Antiretroviral Therapy in Western Kenya

Kaposi’s sarcoma (KS) is a spindle cell tumor resulting from growth dysregulation in the setting of infection with human herpes virus-8 (also called KS herpes virus). Advanced KS is characterized by poor responses to antiretroviral therapy and some of the chemotherapy readily accessible to patients in low-resource areas. Gemcitabine induced partial and complete regression of AIDS-associated KS (AIDS-KS) in 11 of 24 patients in a pilot study. The current study compares the antimetabolite gemcitabine with the standard care bleomycin and vincristine (BV) in the treatment of chemotherapy-naïve patients with AIDS-KS in a resource-limited setting.
Bleomycin, Treatment of Kaposi’s, Antiretroviral, Phase IIA Trial
Busakhala, N. W., Waako, P. J., Strother, M. R., Keter, A. K., Kigen, G. K., Asirwa, F. C., & Loehrer, P. J. (2018). Randomized phase IIA trial of gemcitabine compared with bleomycin plus vincristine for treatment of Kaposi’s sarcoma in patients on combination antiretroviral therapy in Western Kenya. Journal of global oncology, 4, 1-9.DOI: https://doi.org/10.1200/JGO.17.00077